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ABSTRACT
Basal transcription of the HIV LTR is highly
repressed and requires Tat to recruit the positive
transcription elongation factor, P-TEFb, which func-
tions to promote the transition of RNA polymerase II
from abortive to productive elongation. P-TEFb is
found in two forms in cells, a free, active form and a
large, inactive complex that also contains 7SK RNA
and HEXIM1 or HEXIM2. Here we show that HIV
infection of cells led to the release of P-TEFb from
the large form. Consistent with Tat being the cause
of this effect, transfection of a FLAG-tagged Tat in
293T cells caused a dramatic shift of P-TEFb out of
the large form to a smaller form containing Tat.
In vitro, Tat competed with HEXIM1 for binding to
7SK, blocked the formation of the P-TEFb–HEXIM1–
7SK complex, and caused the release P-TEFb from a
pre-formed P-TEFb–HEXIM1–7SK complex. These
findings indicate that Tat can acquire P-TEFb from
the large form. In addition, we found that HEXIM1
binds tightly to the HIV 50 UTR containing TAR and
recruits and inhibits P-TEFb activity. This suggests
that in the absence of Tat, HEXIM1 may bind to TAR
and repress transcription elongation of the HIV LTR.
INTRODUCTION
The positive transcription elongation factor, P-TEFb, is
an essential cellular transcription factor that controls the
transition of RNA polymerase II from abortive to
productive elongation (1–3). P-TEFb is composed of one
of two isoforms of the cyclin-dependent kinase Cdk9 (4,5)
and a partner cyclin, T1, T2 or K (6,7). P-TEFb
phosphorylates serine 2 residues in the heptapeptide
repeat present in the carboxyl terminal domain (CTD)
of the largest subunit of RNA polymerase II (5–7) and
DRB Sensitivity Inducing Factor (DSIF) (8,9), alleviating
the eﬀect of the negative elongation factors DSIF
and Negative ELongation Factor (NELF) (10–12).
Knockdown of P-TEFb subunits by RNAi in
Caenorhabditis elegans reduces serine 2 phosphorylation
in the CTD and the expression of early embryonic genes,
and results in an embryonic lethal phenotype (13).
Inhibition of P-TEFb activity in cells through treatment
with the P-TEFb inhibitor ﬂavopiridol, blocks most RNA
polymerase II transcription, and extended treatment leads
to cell death (14).
P-TEFb was recently found to be regulated by
reversible inhibition via association with the small nuclear
RNA 7SK (15,16) and the RNA-binding proteins
HEXIM1 (17–20) or HEXIM2 (21,22). Association of
7SK with a HEXIM1 dimer relieves an autoinhibitory
interaction between two regions of HEXIM1, allowing
recruitment and inhibition of two P-TEFb molecules
(22–25). The large form of P-TEFb contains potentially
active P-TEFb molecules, because the activating T-loop
phosphorylation of Cdk9 is required for its incorporation
into the large form (25,26). While the exact signals and
mechanisms for mobilization of P-TEFb from the large
form remain undeﬁned, the association of P-TEFb with
7SK and the HEXIM proteins is highly responsive to
intra- and extracellular signaling. For example, the large
form of P-TEFb is disrupted by treatment of cells with
P-TEFb inhibitors, UV light or actinomycin D (15), due
to a poorly understood feedback loop between inhibition
of transcription elongation and P-TEFb activity. Two
physiological models for regulation of P-TEFb activity by
7SK and HEXIM1 have been identiﬁed thus far. Cardiac
hypertrophy has been shown to be a consequence of
activation of P-TEFb in cardiomyocytes through release
from the large complex, which results in an increase in
RNA polymerase II phosphorylation, gene expression and
cell size (27). Conversely, HEXIM1 has been identiﬁed as
a suppressor of breast cancer (28,29).
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genome by utilizing the host cell RNA polymerase II
transcription machinery and is controlled mainly at the
level of elongation. Basal transcription from the HIV long
terminal repeat (LTR) promoter is extremely ineﬃcient,
with most RNA polymerase II initiation events terminat-
ing in abortive elongation (30). Transcription from the
LTR is activated by the viral protein Tat, which facilitates
the transition from abortive to productive elongation (31)
by recruiting P-TEFb (4,32,33). Tat associates with the
transactivation response element, TAR, which is an RNA
stem-loop present in the nascent transcript produced from
the HIV LTR, and P-TEFb containing cyclin T1 is
recruited through association with both Tat and TAR
(33–35). Interestingly, all P-TEFb inhibitors found to date
block HIV replication at lower concentrations than those
that have a negative eﬀect on cellular transcription or
viability (32,36,37). Additionally, over-expression of a
kinase dead Cdk9 mutant reduced the expression of
endogenous Cdk9 and inhibited HIV replication without
aﬀecting cell survival (32,36), and a partial knockdown of
Cdk9 and cyclin T1 did not aﬀect cell viability, yet
inhibited Tat transactivation in Magi cells (38). While the
mechanism of this heightened requirement for P-TEFb
activity in Tat transactivation compared to normal
cellular transcription is not understood, it is possible
that much higher P-TEFb activity levels are required for
HIV to overcome the tight repression of the HIV LTR
promoter. In support of this, it has been shown that for
HIV to replicate in primary blood lymphocytes (PBLs),
the cells must be activated, which causes an increase in
cyclin T1 expression and overall P-TEFb activity (39).
Notably, much of the work regarding the role of P-TEFb
in Tat transactivation was carried out prior to work on
P-TEFb control and the discovery of the large form of
P-TEFb, and its role in HIV replication has only begun to
be explored.
Several lines of evidence led us and others (40–42) to
hypothesize that the large form of P-TEFb is involved in
HIV replication. It has been reported that activation of
PBLs, which leads to increased P-TEFb as discussed
above, causes an increase in 7SK levels along with the
increase in P-TEFb expression, suggesting that activation
of PBLs actually results in an increase in the large form of
P-TEFb (40). The partial knockdown of Cdk9 and cyclin
T1 that blocked Tat transactivation in Magi cells also
eliminated high salt-activated (large form) P-TEFb (38).
Furthermore, the majority of P-TEFb within cells is
actually sequestered within the large complex. Taken
together with the P-TEFb inhibition studies demonstrat-
ing that HIV requires much higher levels of P-TEFb
activity than cellular promoters, this suggests that the
P-TEFb within the large complex is necessary for HIV
replication, and furthermore, that HIV has a mechanism
to subvert normal cellular control and activate P-TEFb.
This activation would provide a larger pool of P-TEFb for
use at the HIV LTR (32,36,37). In support of this
hypothesis, low levels of actinomycin D, which inhibit
transcription and lead to release of P-TEFb from the large
form without inhibition of P-TEFb itself (15), have been
shown to activate the HIV LTR in the absence of Tat (43),
suggesting that the HIV LTR may be able to use the
P-TEFb obtained from the large complex. Our current
studies were designed to uncover details of how HIV
interfaces with the cellular factors that control P-TEFb.
MATERIALS AND METHODS
Cell linesand compounds
All cells were grown under standard conditions of 378C,
5% CO2. HeLa37 cells, which express CD4 and both
CXCR4 and CCR5 (44), were grown in DMEM with 10%
FBS and 1  penicillin/streptomycin (pen/strep). HeLa S3
cells were grown in DMEM-F12 with 10% FBS. 293T
cells were obtained as a kind gift from P. McCray (Univ.,
Iowa). Cells were maintained in DMEM with 10% fetal
calf serum and pen/strep. Cells were trypsinized and split
1:10 every 4 days.
Antibodies
Anti-Cdk9 (C-20) was obtained from Santa Cruz (sc-484).
Anti-FLAG M2-peroxidase (HRP) was obtained from
Sigma (A8592). Anti-cyclin T1 (T-18) used in western
blots was obtained from Santa Cruz (sc-8127). Anti-cyclin
T1 used in EMSA was generated in sheep recognizing the
C-terminal domain (Abcam ab27963).
Generation ofHIV p256 or VSVG pseudotyped p256 viral
stocks
Here, 293T cells were seeded at 5 10
5cells/well in a six-
well tray a day before transfection with 7mg of p256
proviral DNA or cotransfection with 6.5mg of p256
proviral DNA and 0.5mg of VSVG-expressing plasmid
using the CaPO4 procedure (45) to generate p256 and
VSVG pseudotyped p256 viral stocks, respectively. Virus-
containing supernatants were collected at 24, 48, 72 and
96h post-transfection and virus production was measured
by titering the cell-free supernatants of p256 on HeLa37
cells and VSVG pseudotyped virions on HeLa S3 cells.
HIV infection
HeLa37 cells were infected with dual-tropic HIV p256at
an MOI of 0.1 for glycerol gradient analysis. After 4 days,
the cells were lifted from the plate.A total of 4 10
4 cells
were re-plated and immunostained for HIV antigens. The
remaining cells were harvested and washed with 1  PBS
containing 1ml/ml protease inhibitor cocktail (Sigma).
Lysates were prepared to extract all P-TEFb and subjected
to glycerol gradient sedimentation at 45000r.p.m. for 16h
as described below.
Transfection and Expression of HIV Tat
pFLAG-CMV2-Tat was created by cloning HIV-1 Tat
(amino acids 1–86) in frame with the amino terminal
FLAG-tag in pFLAG-CMV2 (Sigma) using EcoRI and
BamHI restriction sites. Here, 293T cells were trypsinized
and 3 10
6 cells were plated on a 150-mm plate. The next
day when cells were  80% conﬂuent, the media was
refreshed prior to calcium phosphate transfection.
Seventy-ﬁve micrograms of plasmid DNA was added to
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EDTA. This tube was mixed well and maintained at 378C
until mixed in a dropwise fashion with 1ml of 2  HBS
(50mM HEPES, 1.5mM Na2HPO4 and 140mM NaCl,
pH 7.05) that was also held at 378C. Mixture was vortexed
thoroughly and added in a dropwise manner to the plate
of cells. Media was refreshed at 12h post transfection and
maintained for an additional 30–36h. At the termination
of the transfection, a small population of the cells were
immunostained for FLAG expression in a 48-well tray.
Cells were ﬁxed with 3.7% paraformaldehyde for 20min
followed by 3 1ml washes with PBS. Cells were
permeabilized with 0.25% Triton X-100 in PBS for
20min and washed extensively with PBS at the completion
of the incubation. Cells were incubated with PBS contain-
ing 5% fetal calf serum (FCS) to block non-speciﬁc
binding. Anti-FLAG monoclonal antibodyM2 (Sigma)
was diluted 1:1250 in PBS with 5% FCS and incubated
with the cells for 2h at 378C. Cells were rinsed three times
with PBS and peroxidase-conjugated goat anti-mouse
antisera (1:1000) was added until the reaction was
suﬃciently developed. The remaining cells were harvested
and washed with 1  PBS, and cell lysates were prepared
to extract all P-TEFb and subjected to glycerol gradient
sedimentation at 45000r.p.m. for 16h as described below.
Glycerol gradientsedimentation analysis ofcell lysates
Cell lysates were prepared in Buﬀer A (10mM KCl,
10mM MgCl2, 10mM HEPES, 1mM EDTA, 1mM
DTT, 0.1% PMSF and EDTA-free complete protease
inhibitor cocktail from Roche) containing 150mM NaCl
and 0.5% NP-40 as previously described (15,21). The
lysates were clariﬁed by centrifugation at 14000r.p.m. for
10min at 48C in a microfuge. The supernatant was used as
input for 4.8ml, 5–45% glycerol gradients, in Buﬀer A
with 150mM NaCl, spun at 45000r.p.m. for 20 or 16h in
a SW-55Ti rotor in a L7-55 Beckman ultracentrifuge as
previously described (15,21). The fractions were analyzed
by western blotting with anti-cyclin T1 or anti-Cdk9 for
P-TEFb, and a HRP-conjugated M2 FLAG antibody for
FLAG-Tat. Following incubation with the appropriate
HRP-conjugated secondary antibody, when necessary, the
blots were treated with Super Signal Dura West (Pierce).
The western blots were imaged with a cooled CCD camera
(UVP) and the P-TEFb signals in the fractions containing
the free and large forms of P-TEFb, as indicated in the
ﬁgures, were quantitated with Lab Works 4.0.
Kinase assay
Kinase reactions were carried out with recombinant
puriﬁed P-TEFb [Cdk9/cyclin T1 (1–290)] and DSIF in
30mM KCl, 20mM HEPES pH 7.6, 7mM MgCl2,3 0mM
ATP, 2.5mCi of [g-
32P]-ATP (Perkin–Elmer) with 1mg
BSA. The reactions were incubated for 20min at 308C and
stopped by the addition of SDS–PAGE loading buﬀer.
Reactions were resolved by SDS–PAGE on a 7.5%
polyacrylamide gel. The dried gel was subjected to
autoradiography and quantitation was performed using
an InstantImager (Packard).
Equilibrium electrophoretic mobility shift assay(EMSA)
Twelve-microliter reactions were carried out in 25mM
HEPES, pH 7.6, 15% glycerol, 60mM KCl, 10mM DTT,
0.01% NP-40, 1mg BSA with 200ng yeast tRNA
(Invitrogen) with or without 15mM ZnCl2 as indicated,
and including T7 transcribed, radiolabeled 7SK, recombi-
nant Tat (NIH AIDS reagents program), HEXIM1, and
P-TEFb containing cyclin T1 as indicated. Cold RNA
oligos for competition studies were chemically synthesized
(IDT). 7SK and tRNA were heated for 5min at 758C and
cooled on ice for another 5min, prior to addition.
Reactions were incubated at room temperature for
20min and resolved on a 4% polyacrylamide gel in 0.5 
Tris/glycine at room temperature for 2h at 4W. The dried
gel was subjected to autoradiography.
Stoichiometric EMSA
Twelve-microliter reactions were carried out in 25mM
HEPES, pH 7.6, 15% glycerol, 60mM KCl, 15mM ZnCl2,
5mM DTT and 0.01% NP-40, including 50ng of
chemically synthesized TAR RNA (nucleotides 1–59)
(Dharmacon), 640c.p.m. of T7-transcribed radiolabeled
TAR RNA, HEXIM1 and P-TEFb containing cyclin T1
(residues 1–290), as indicated. TAR RNA was heated for
5min at 758C and cooled on ice for another 5min, prior to
addition. Reactions were incubated at room temperature
for 10min and resolved on a native 5% polyacrylamide
gel in 0.5  Tris/glycine at 48C for 1.5hat 4W. The dried
gel was subjected to autoradiography.
RESULTS
The large form ofP-TEFb is reduced during HIV infection
Because most P-TEFb is found in the large inactive
complex, and because several studies suggested that HIV
requires higher P-TEFb activity than cellular promoters,
we decided to test the hypothesis that HIV is able to
release P-TEFb from the large form. First, the eﬀect of
HIV on the large form of P-TEFb was investigated
through examination of the relative levels of the free and
large forms of P-TEFb in HIV infected cells. HeLa37 cells
were infected with the dual tropic HIV virus p256 (46) at
an MOI of 0.1. Four days post-infection, the HeLa37 cells
were determined to be  96% positive for the production
of viral proteins by immunohistochemistry. The cells were
lysed to extract all of the P-TEFb and the forms of
P-TEFb were analyzed by glycerol gradient sedimentation
and quantitative western blotting (Figure 1A).
Qualitatively, there is an obvious shift of both cyclin T1
and Cdk9 from the large to the small form following HIV
infection. The Cdk9 signals for the small and large forms
of P-TEFb from two experiments were averaged and SDs
calculated (Figure 1B) to reveal that 84% 1% of
P-TEFb was found in the large form in untreated cells,
whereas after 4 days of HIV infection, 72% 3% of
P-TEFb remained in the large form. The change in the
relative level of the large form of P-TEFb by HIV
infection suggests that HIV is able to release and utilize
P-TEFb obtained from the large form.
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thelarge form in vivo
Because the main diﬀerence between the activation of
normal cellular promoters and the HIV LTR is the
requirement for Tat and it is known that Tat is able to
interact with P-TEFb, we hypothesized that the shift from
large to free form observed during HIV infection was due
to the expression of Tat in the HIV infected cells. To
investigate this possibility, the eﬀect of Tat on the large
and small forms of P-TEFb present in uninfected cells was
examined. In two separate experiments, 293T cells were
transiently transfected with a construct expressing an
N-terminally FLAG-tagged Tat. After 48h, the cells were
lysed and the P-TEFb was analyzed by glycerol gradient
sedimentation and fractionation followed by quantitative
western blotting. In control untransfected or b-Gal
transfected 293T cells, most of the P-TEFb ( 90%) is
found in the large, inactive form [Figure 2A (fractions
11–15) and B (fractions 9–12)]. In cells expressing HIV
Tat, there was a signiﬁcant shift in P-TEFb from the large,
inactive form to fractions that normally contain the free
form [Figure 2A (fractions 6–10) and B (fractions 5–8)].
Quantitation of the amounts of Cdk9 indicated that in the
ﬁrst experiment, expression of Tat caused a reduction of
the large form from 90 to 56%. In the second experiment,
the large form was reduced from untransfected control
and b-Gal control (89 and 81%, respectively) to 36%.
The transfection eﬃciency was not the same in the two
experiments and, interestingly, the fractional change in the
large form of P-TEFb correlated with the fraction of cells
observed by immunostaining to be expressing Tat. This
suggests that all of the P-TEFb was released from the large
form within the transfected cells and that the remaining
large form detected on the gradient was derived from
untransfected cells. The larger change seen in these
experiments compared to the experiment in which cells
were infected with HIV is most likely due to the fact that
Tat is present in higher amounts after transient transfec-
tion with a plasmid expressing Tat from the CMV
promoter compared to the expression of Tat during HIV
infection.
In cells expressing HIV Tat, the glycerol gradient
fractions containing the ‘free’ form of P-TEFb appear to
be shifted slightly down the gradient compared to
untransfected or b-Gal transfected cells, and Tat, with a
molecular weight of 15kDa, appears to co-sediment with
the small form of P-TEFb, a complex with a molecular
weight of at least 120kDa (Figure 2A and B). These
observations suggest that Tat is bound to P-TEFb, and, in
fact, co-immunoprecipitation of P-TEFb and HIV Tat
from these fractions conﬁrmed this interaction (data not
shown). This association is consistent with many previous
studies demonstrating Tat association with P-TEFb
(4,39,47,48). Although an interaction with Brd4 and
P-TEFb has been recently described (49–51) we do not
think that expression of Tat in cells leads to the formation
of a P-TEFb–Brd4 complex. The P-TEFb in fractions 4–8
of the glycerol gradients does not contain Brd4 because
the 150mM salt conditions used to extract P-TEFb from
the nucleus do not extract Brd4. The interaction between
Brd4 and P-TEFb can only be observed if nuclei are
extracted with high salt (4300mM) and then dialyzed
down to low salt (50,51). From these studies we conclude
that expression of Tat leads to the disruption of the large
form and the formation of a Tat–P-TEFb complex.
HIV Tat binds to7SK, competes withHEXIM1 anddisrupts
the large formof P-TEFb in vitro
The in vivo studies just presented indicate that the
expression of Tat leads to the release of P-TEFb from
the P-TEFb–HEXIM1–7SK complex and to the forma-
tion of a P-TEFb complex. However, due to the ambiguity
of the in vivo system, it is not clear whether this release is
due to a direct eﬀect of Tat on the complex or more a
more indirect eﬀect, such as Tat association with P-TEFb
complex leading to lower levels of P-TEFb activity and
less general transcription that might trigger the cellular
mechanism that releases P-TEFb from the large form.
Because of this, a deﬁned in vitro system was used to
investigate the biochemical mechanism of this release.
EMSAs were carried out under equilibrium binding
conditions with protein in vast excess over
32P-labeled
in vitro transcribed full-length 7SK. Two-hundred nano-
grams of highly structured tRNA (41000-fold excess over
7SK) was used in each reaction as a non-speciﬁc comp-
etitor instead of poly (rI):poly (rC) that was used
previously (19,21,25,52) because we recently found that
HEXIM1 binds tightly to dsRNA (53). Dimeric HEXIM1
(25) formed its characteristic speciﬁc complex with 7SK
Figure 1. HIV infection leads to activation of P-TEFb. (A) HeLa37
cells were infected with p256 HIV at an MOI of 0.1. After 4 days, the
lysates of HIV infected HeLa37 cells and a parallel culture of
uninfected HeLa37 cells were lysed to extract all P-TEFb and subjected
to glycerol gradient sedimentation. The fractions were examined by
quantitative western blotting for Cdk9 and cyclin T1 as indicated.
(B) Cdk9 was quantitated for small and large forms of P-TEFb,
in either uninfected or infected HeLa37 cells, from duplicate experi-
ments and averages were calculated and plotted. Error bars represent
 1 SD of the mean.
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ing amounts of Tat were added to 7SK a more slowly
migrating complex formed, demonstrating that Tat can
bind to 7SK forming a Tat–7SK complex. A portion of
the 7SK was also shifted into the well and this could be
due to association of 7SK with oxidized aggregates of Tat.
When HEXIM1 was pre-incubated with 7SK to form the
HEXIM1–7SK complex and then increasing amounts of
Tat were added before being loaded onto the native gel,
the HEXIM1–7SK complex was gradually eliminated and
was replaced by a Tat–7SK complex. When the Tat–7SK
complex was preformed and then HEXIM1 was added,
the competition was even stronger. The amounts of the
Tat–7SK complex formed were virtually identical with or
without HEXIM1 being present. The fact that larger
molar amounts of Tat were required is likely due to the
presence of a large fraction of inactive Tat in the
preparation used. We conclude that Tat can compete
strongly with HEXIM1 for binding to 7SK, and that even
when the relatively stable HEXIM1–7SK complex is
preformed, Tat can disrupt it. There was no evidence for
a signiﬁcant amount of a Tat–HEXIM1–7SK complex,
indicating that Tat and HEXIM1 bind to an identical or
overlapping region of 7SK or that Tat and HEXIM1 bind
to diﬀerent mutually exclusive conformations of 7SK.
We next examined the eﬀect of Tat on the P-TEFb–
HEXIM1–7SK complex. In control reactions, the pre-
viously observed HEXIM1–7SK and Tat–7SK complexes
were found. P-TEFb, containing Cdk9 and full-length
cyclinT1, formed non-discrete complexes with 7SK
(Figure 3B). This is likely due to a weak, perhaps non-
speciﬁc, interaction of P-TEFb and 7SK. A combination of
Tat and increasing amounts of P-TEFb also gave
a progression of non-speciﬁc shifts. However, when
HEXIM1 and increasing amounts of P-TEFb were added
together, the HEXIM1 shift gradually disappeared and a
very discrete band containing HEXIM1 and P-TEFb
formed (Figure 3B, P–H1–7SK). To investigate the direct
eﬀect of Tat on formation of a P-TEFb–HEXIM1–7SK
complex, HEXIM1, P-TEFb and increasing amounts
of HIV Tat were pre-incubated followed by the
addition of 7SK. As Tat was titrated into the rea-
ctions, a dose-dependent inhibition of the formation of
the P-TEFb–HEXIM1–7SK complex resulted with the
Figure 2. HIV Tat releases P-TEFb from the large form in vivo.( A) 293T cells were transiently transfected with a HIV Tat-expressing construct
containing a N-terminal FLAG tag. After 48h, control 293T cells (b-Gal-transfected) and FLAG-Tat transfected 293T cells were lysed to extract all
P-TEFb and subjected to glycerol gradient sedimentation. The gradient fractions were analyzed by quantitative western blotting for Cdk9 or FLAG-
Tat, as indicated. (B) Repeat experiment, as in (A), with an additional mock transfection control (Control) and with higher transfection eﬃciencies.
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HEXIM1–7SK complex. Under these conditions in the
presence of P-TEFb, there was no evidence for a Tat–7SK
complexsuggesting thatTat was ableto blockformation of
the P-TEFb–HEXIM1–7SK complex without blocking
HEXIM1 binding.
Because Zn
2+ has been shown to be required for
eﬃcient interaction between P-TEFb and Tat (35),
EMSAs were performed in the presence of 15mM
ZnCl2. HEXIM1 and Tat still formed speciﬁc complexes
with 7SK while the weak interaction of P-TEFb with
7SK was made even weaker as evidenced by higher
migration rate of 7SK compared to the rate in the
absence of zinc (Figure 4A). Now, in the presence of zinc,
there was evidence of a P-TEFb–Tat–7SK complex.
When roughly equimolar amounts of P-TEFb and
HEXIM1 (30 and 10ng, respectively) were combined
with 7SK, a shift of the HEXIM1–7SK complex was
again observed, with supershift of the complex by an
aﬃnity-puriﬁed antibody directed towards the C-terminal
domain of cyclin T1 conﬁrming the presence of P-TEFb
and the formation of the P-TEFb–HEXIM1–7SK com-
plex. Upon titration of HIV Tat into reactions containing
30ng of P-TEFb and 10ng of HEXIM1, there was again
a dose-dependent inhibition of the formation of the P-
TEFb–HEXIM1–7SK complex. Under these conditions,
there was only a very small amount of Tat–7SK complex
formed at the highest Tat concentration. When similar
reactions containing only 10ng of P-TEFb were ana-
lyzed, more of the Tat–7SK complex was seen at high
levels of Tat. In reactions containing 10ng of HEXIM1
with 30ng P-TEFb and 30ng Tat or with 10ng P-TEFb
and 10ng Tat, most of the P-TEFb–HEXIM1–7SK
complex was gone and the HEXIM1–7SK complex was
clearly visible. This ﬁnding is not easily explained by a
simple competition between Tat and HEXIM1 for
binding to 7SK, but rather suggests that under these
conditions with zinc, a Tat–P-TEFb complex forms
which does not allow P-TEFb to be recruited by the
HEXIM1–7SK complex. Several shifts are visible at high
levels of Tat that likely represent Tat–P-TEFb–7SK
complexes (Figure 4A, Tat–P–7SK). A supershift by
anti-cyclin T1 conﬁrmed the presence of P-TEFb in these
complexes. It is possible that the two major shifts in this
region represent Tat–P-TEFb–7SK complexes with one
or two molecules of P-TEFb per complex.
Figure 3. HIV Tat competes with HEXIM1 for binding to 7SK and
inhibits the formation of the P-TEFb–HEXIM1–7SK complex (A) The
binding of 10ng of HEXIM1 or the indicated amounts of Tat recombi-
nant proteins to in vitro transcribed, radiolabeled 7SK was evaluated
by electrophoretic mobility shift assay (EMSA) under equilibrium
conditions as described in Materials and Methods. The proteins were
added to the radiolabeled 7SK individually or HEXIM1 (H1) was
added 10min before the indicated amounts of Tat (HEXIM1/Tat) was
added for an additional 10min. Reactions were also carried out with
the indicated amounts of Tat added to 7SK before 10ng of HEXIM1
(Tat/HEXIM1) was added. Complexes were resolved by gel electro-
phoresis on a native gel and visualized by autoradiography. (B) The
ability to form a P-TEFb–HEXIM1–7SK complex or inhibit formation
of the complex was evaluated by titrating the indicated amounts of
P-TEFb and/or Tat onto a preformed HEXIM1–7SK complex
containing 3ng of HEXIM1 and resolving complexes as in (A).
Figure 4. HIV Tat inhibits the formation of and disrupts a preformed
P-TEFb–HEXIM1–7SK complex. (A) To determine the mechanism of
inhibition of complex formation, the indicated amounts of recombinant
P-TEFb (P), HEXIM1 (H1) and HIV Tat (Tat) were added to
radiolabeled 7SK in the presence of Zn
2+, incubated for 15min, and
the complexes resolved by gel electrophoresis on a native gel.
Supershifts were carried out by adding aﬃnity-puriﬁed anti-cyclin T1
(T1) to reactions containing
32P-7SK, Tat–P-TEFb–7SK and P-TEFb–
HEXIM1–7SK and incubating for an additional 10min to verify the
presence of P-TEFb. (B) Inhibition of P-TEFb–HEXIM1–7SK complex
formation was evaluated with EMSA by pre-incubating the indicated
amounts of P-TEFb, HEXIM1 and HIV Tat for 5min, followed by
addition of radiolabeled 7SK and incubation for an additional 15min.
To evaluate P-TEFb–HEXIM1–7SK complex disruption, the indicated
amounts of P-TEFb, HEXIM1 and 7SK were pre-incubated for 10min
to allow formation of the complex, followed by addition of increasing
amounts of HIV Tat and incubation for an additional 10min.
Complexes were resolved and visualized as in (A).
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HEXIM1–7SK complex formation and to determine if
Tat could disrupt a preformed complex, EMSA was again
used (Figure 4B). Again, Tat was observed to inhibit the
formation of the P-TEFb–HEXIM1–7SK complex
(Figure 4B, Inhibition). Additionally, as more P-TEFb
was added to a constant amount of HEXIM1 in the
absence of Tat (compare the ﬁrst lane in each set of
P-TEFb levels), there was the expected progressive shift of
the HEXIM1–7SK complex to the P-TEFb–HEXIM1–
7SK complex. As increasing amounts of Tat were included
in the reactions, there was a progressive decrease in the
P-TEFb–HEXIM1–7SK complex formed and corre-
sponding increases in the HEXIM1–7SK complex and
the previously postulated Tat–P-TEFb–7SK complexes.
Interestingly, as the amount of P-TEFb was increased in
the reactions, there was a progressive shift from the lower
Tat–P-TEFb–7SK band to the upper band (compare the
last lane of each set of P-TEFb), supporting the hypothesis
that the upper band is a Tat–P-TEFb–7SK complex
containing two molecules of P-TEFb. Again, only at the
highest concentrations of Tat, after all P-TEFb has been
bound by Tat, was the Tat–7SK complex observed. To
determine if Tat is able to disrupt a preformed large
complex, P-TEFb–HEXIM1–7SK complexes were formed
before addition of Tat. As more Tat was added to pre-
formed P-TEFb–HEXIM1–7SK complexes, there was a
disruption of the complex, with formation of HEXIM1–
7SK, Tat–P-TEFb–7SK, but not the Tat–7SK complexes
(Figure 4B, Disruption). Disruption of pre-formed
P-TEFb–HEXIM1–7SK complexes by Tat appeared less
eﬃcient than inhibition of complex formation when the
amount of P-TEFb–HEXIM1–7SK remaining at corre-
sponding amounts of Tat is compared between the two
experiments. Overall, these data demonstrate that Tat can
prevent the formation of a P-TEFb–HEXIM1–7SK
complex and can disrupt a preformed P-TEFb–
HEXIM1–7SK complex.
Tat binds tonucleotides 10–48 of7SK
To gain insight into what sequence Tat recognized in 7SK,
the ﬁrst 100nt of 7SK were compared to HIV TAR, and a
set of oligos were designed and tested for their ability to
block Tat binding to 7SK. The target for Tat binding in
TAR consists of an AUCUG forming a bulge in the apical
region of the TAR stem-loop and this binding of Tat
changes the structure of TAR so that a pocket forms
between U23 and G26 (54–56). When the sequence of 7SK
was analyzed, three AUCUG motifs were found
(Figure 5A). This sequence would be expected to occur
randomly once every 4
5bp, or about 1 in 1000nt, and so it
may be signiﬁcant that it is found three times in the ﬁrst
100nt of 7SK. A set of oligos were designed that
contained AUCUG sequences in the context of sequences
that would be unstructured or that could form secondary
structure with the AUCUG in loops or in bulges. Other
regions of 7SK were also sampled as controls (Figure 5A).
mFold suggested that 7SK (10–48) would form a stem-
loop with one AUCUG in a bulge and one in the loop and
is shown compared to TAR in Figure 5B. HEXIM1 has
been demonstrated to bind to a region of in the 50 end of
7SK (57) and to this speciﬁc oligo as well as it binds to
intact 7SK (53). Unlabeled oligos were then used as
competitors in EMSAs with labeled full-length 7SK and
Tat. No competition was seen for any of the oligos except
for 7SK (10–48) (Figure 5C and D). This strongly suggests
that Tat associated with the residues from 10 to 48 of 7SK.
Because no competition was seen with oligos comprised of
11–34 or 20–36, Tat may require the secondary structure
shown in Figure 5B to be able to interact with 7SK.
Figure 5. HIV Tat binds to a region of 7SK resembling TAR.
(A) Analysis of the sequence of 7SK reveals three AUCUG Tat
consensus-binding sites in the ﬁrst 100nt. Several structured and
unstructured RNA oligos with or without this consensus sequence were
designed and chemically synthesized with most coming from the native
7SK sequences indicated. 7SK (10–48M) has one insertion and one
deletion in an otherwise wild-type 7SK (10–48) sequence. (B) Predicted
structures of all oligos with suﬃcient stability to be the predominate
form at room temperature. (C) Competition EMSA analysis of
Tat–7SK complex formation. Tat,
32P-labeled 7SK, and the indicated
cold RNA oligos were pre-incubated and the resulting complexes were
resolved by gel electrophoresis on a native gel, followed by
autoradiography to visualize the 7SK shift. The dsRNA was a 25-bp
double-stranded RNA unrelated to 7SK sequence described previously
(53). (D) Competition EMSA comparison between 7SK (10–48) and
7SK (10–48M). Note in this experiment the 7SK was of higher speciﬁc
activity than in (C) so less Tat was needed to achieve a higher fraction
of Tat–7SK complex.
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Tat with 7SK, a new oligo similar to 7SK (10–48) was
used in a competition EMSA assay. The mutant oligo,
7SK (10–48M), was identical to 7SK (10–48) except that
an A was inserted in the ﬁrst AUCUG site (AUCAUG)
and U40 was deleted (Figure 5A). These two changes
eliminated the bulge region to which we thought Tat
might bind and increased the length of the stem
(Figure 5B). The mutant oligo serves as a control for the
potential binding of Tat to any RNA that contains a stem
and loop with a bulge. As was seen above, as increasing
amounts of the 7SK (10–48) were included in reactions
containing Tat and
32P-7SK, the Tat–7SK shift was
decreased with 100ng of the oligo and completely
eliminated with 1000ng of the oligo (Figure 5E). In
contrast, 7SK (10–48M) only partially blocked Tat
binding to 7SK at the highest level of oligo. We conclude
that the changes in the 7SK 10–48 oligo lowered the
aﬃnity of Tat. Our results up to this point indicate that
Tat binds to 7SK in a speciﬁc manner and that the region
of 7SK to which Tat binds is from nucleotides 10–48.
HEXIM1binds to TAR RNA and inhibits P-TEFb
Given the previous results demonstrating that HEXIM1
and Tat compete for binding to the same small 7SK oligo,
and the similarity of this region with the TAR RNA, we
explored the possibility that HEXIM1 might bind to
TAR. If this is the case, it might also be able to bind and
inhibit P-TEFb much the same way that HEXIM1 and
7SK inhibit P-TEFb, thus repressing P-TEFb, and
transcription elongation, at the HIV LTR promoter. To
begin testing this hypothesis, EMSAs were used to
determine if HEXIM1 could bind to TAR and recruit
P-TEFb.
32P-labeled, chemically synthesized TAR
RNA was combined with FPLC-puriﬁed HEXIM1,
and P-TEFb containing Cdk9 and the ﬁrst 290 amino
acids of cyclin T1, as indicated; complexes were resolved
on a native gel and both silver-stained and exposed to
ﬁlm to visualize both the RNA and protein shifts
(Figure 6). When HEXIM1 and TAR were combined,
a new complex migrating more slowly than either
HEXIM1 or TAR RNA was observed, suggesting the
formation of a HEXIM1-TAR complex (Figure 6,
H1–TAR). As P-TEFb was titrated onto this complex,
there was a further shift of the complex with more
mobility than free P-TEFb, accompanied by a change in
the color of the silver-stained gel complex, suggesting
the addition of a new component and the formation of
a P-TEFb–HEXIM1–TAR complex (Figure 6, H1–P–
TAR). More importantly, free P-TEFb, which does not
bind to RNA alone, disappeared.
While this result supports the hypothesis that HEXIM1
can bind to TAR, with subsequent recruitment and
binding of P-TEFb, inhibition of P-TEFb requires that
the RNA change the conformation of HEXIM1 to relieve
the autoinhibitory properties of the protein. To determine
whether HEXIM1–TAR can inhibit P-TEFb, in vitro
kinase assays were performed using recombinant
P-TEFb(1–290), HEXIM1 and TAR RNA as in the
EMSAs to monitor g-
32P(ATP) incorporation into DSIF,
and the complexes resolved by SDS–PAGE (Figure 7A).
Compared to P-TEFb alone and with DRB, an inhibitor
of P-TEFb, there was no qualitative eﬀect of HEXIM1
alone on P-TEFb kinase activity. Similarly, TAR alone,
or 7SK alone as a control, demonstrated no appreciable
eﬀect. However, when HEXIM1 and TAR are combined
and titrated in a constant ratio determined by EMSA
to give 1:1 HEXIM1–TAR binding, there was a dose-
dependent inhibition of P-TEFb, similar to that observed
Figure 7. HEXIM1–TAR inhibits the kinase activity of P-TEFb.
(A) HEXIM1, TAR RNA, 7SK RNA or mixtures of HEXIM1 and
TAR or 7SK found by EMSA to result in 1:1 HEXIM1–TAR or
HEXIM1–7SK complexes were titrated into in vitro kinase assays
containing puriﬁed P-TEFb and incorporation of
32P into the Spt5
subunit of DSIF was analyzed by SDS–PAGE followed by autoradio-
graphy. (B) Kinase activity of P-TEFb in the presence HEXIM1, TAR
and 7SK as described in (A) was quantitated using an Instant Imager
and plotted as a function of increasing HEXIM1.
Figure 6. HEXIM1 binds TAR and the HEXIM1–TAR complex
recruits P-TEFb. The binding of HEXIM1, TAR and P-TEFb was
evaluated under stoichiometric conditions by EMSA. The indicated
components were pre-incubated and the resulting complexes were
resolved by gel electrophoresis on a native gel. The gel was silver-
stained to visualize protein shifts and autoradiography used to visualize
the
32P-labeled RNA shifts.
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(Figure 7B), HEXIM1 and the RNAs separately had no
signiﬁcant eﬀect; however, HEXIM1–TAR appeared to
inhibit as eﬀectively as equimolar amounts of HEXIM1–
7SK. These ﬁndings support the hypothesis that HEXIM1
may actually be inhibiting P-TEFb at the HIV LTR.
DISCUSSION
The initial goal of this work was to examine the role of
P-TEFb in the large form in HIV replication. In the course
of our studies a number of important ﬁndings were made
that can be applied toward understanding how P-TEFb is
regulated and how the P-TEFb regulatory machinery may
be used during HIV replication. Importantly, we found
that the large form of P-TEFb was reduced during viral
infection of HeLa37 cells. Furthermore, expression of
HIV Tat in 293T cells was suﬃcient for release of P-TEFb
from the large form. In vitro binding studies indicated that
Tat could bind to 7SK and could block the formation of
the P-TEFb–HEXIM1–7SK complex, and could remove
P-TEFb from a preformed large complex. Finally, we
found that HEXIM1 could bind to HIV TAR, and recruit
and inhibit P-TEFb in vitro.
HIV Tat activates thelarge form of P-TEFb
The results presented in this study strongly suggest that
the large form of P-TEFb is involved in the positive
regulation of HIV replication. Interestingly, upon infec-
tion with HIV, there was a decrease in the large form of
P-TEFb, and we subsequently demonstrated that the HIV
Tat protein in the absence of other viral proteins or RNAs
could release P-TEFb from the large form, with the
formation of a Tat–P-TEFb complex. Potentially relevant
to this, actinomycin D, which globally inhibits transcrip-
tion, has been shown to cause release of P-TEFb from the
large form and can also activate transcription from the
HIV LTR in the absence of Tat (43). Presumably, this is
due to increased P-TEFb activity. This data suggests that
HIV replication does not require the large form per se, but
rather requires higher levels of P-TEFb activity than
cellular promoters to overcome the inherent negativity of
the HIV LTR. Because the vast majority of P-TEFb is
within the large form, HIV may have developed a
mechanism to increase P-TEFb activity required for
productive elongation from the HIV LTR via Tat-
mediated release from the large complex. However,
increasing P-TEFb activity has deleterious eﬀects within
the cell, as it has been shown that excess P-TEFb in
cardiomyocytes leads to apoptosis (58) and disequilibrium
between the large and free forms of P-TEFb due to
exogenous expression of P-TEFb subunits results in
degradation of endogenous P-TEFb in order to maintain
constant P-TEFb levels (59,60). In using Tat, HIV is not
only using its genome eﬃciently, as Tat is the factor that
ultimately recruits P-TEFb to the LTR, it may also be
masking the increase in P-TEFb activity by not releasing
‘free’ P-TEFb, but instead forming a Tat–P-TEFb
complex. This complex might not be able to function at
cellular promoters because of its inability to interact with
other transcription factors, as evidenced by the ability of
Tat to inhibit CIITA function (48).
While Tat can compete with HEXIM1 for binding to
7SK, it appears that the mechanism by which Tat is able
to release and activate P-TEFb from the large form may
be via direct interaction with P-TEFb and inhibition of the
formation of the large complex and/or direct disruption of
it. Figure 8 shows all the complexes examined in this
study. Where possible, relative interaction potentials
(labeled with letters) were estimated from the studies
presented. We were not able to detect any inﬂuence of
P-TEFb on the interaction between Tat and 7SK, so A
and D are similar. Likewise P-TEFb did not seem to
inﬂuence the interaction of HEXIM1 with 7SK so B and F
are similar. Because Tat was able to compete well with
HEXIM1 for binding to 7SK, A and D may be slightly
stronger than B and F. It was not possible to determine
the relative interaction potential between P-TEFb and Tat
compared to the RNA binding proteins and 7SK so a
second hierarchy was created. Because the interaction of
Tat and P-TEFb was not aﬀected by 7SK, C is similar to
G. Most importantly, P-TEFb preferred to interact with
Tat rather than the HEXIM1–7SK complex, so G is
stronger than E. Finally one of the biggest diﬀerences
between Tat and HEXIM1 is that HEXIM1, but not Tat,
requires 7SK to evoke a conformational change necessary
for interaction with P-TEFb. This means that E is much
greater than H. While the relative interaction potentials
help explain what was observed in vitro and are consistent
with what we found in cells, the in vivo situation is
complicated by the presence of other proteins that may
interact with 7SK. HEXIM1 is not found in association
with 7SK in the absence of P-TEFb even though it has
high aﬃnity for the RNA. It is possible that the Tat–7SK
interaction is also eliminated in vivo by a similar
mechanism and this would in turn favor the formation
of the Tat–P-TEFb complex.
HEXIM1repression of theHIV LTR promoter
As previously discussed, the high sensitivity of HIV
transcription to P-TEFb inhibitors compared to cellular
transcription suggests that HIV requires much higher
P-TEFb activity to overcome the inherent repression of
the HIV LTR. The basis of this negativity, however,
remains controversial. Some have suggested that it is due
to recruitment of NELF (61). Unfortunately, this may not
adequately account for the diﬀerential repression observed
Figure 8. Relative interaction potentials. All complexes examined in
this study are indicated and the various protein–protein and protein–
RNA interactions are lettered. As described in the text, two hierarchies
of interaction potentials are indicated.
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present at cellular promoters. During the course of these
studies, clues to the basis of the repression of the HIV
LTR promoter were discovered which allow for an
alternative model to be proposed. It was found that
HEXIM1 can bind to the TAR RNA element that is
normally found in the nascent transcript generated from
the HIV LTR promoter. Furthermore, this HEXIM1–
TAR complex was shown to be able to recruit and bind
P-TEFb, eﬀectively inhibiting P-TEFb in the same manner
as HEXIM1–7SK. From this, we hypothesize that the
recruitment of HEXIM1 by TAR leads to repression of
the HIV LTR. Only when there are abnormally high levels
of P-TEFb, such as in the presence of low levels of
actinomycin D, or when Tat is present would productive
elongation from the HIV LTR be allowed.
In examining the control of P-TEFb or HIV LTR
function several groups inadvertently provided evidence
for a direct eﬀect of HEXIM1 on the expression of the
HIV LTR. When HEXIM1 was overexpressed in cells it
had a negative eﬀect on basal expression from an HIV
LTR reporter gene (17,20,22,62). This eﬀect did not
require a functional TAR region of the HIV 50 UTR
because an LTR reporter containing a mutation in the
UCU bulge that stops Tat transactivation gave the same
result. Inhibition did require the RNA binding domain
and the P-TEFb inhibitory domain of HEXIM1 (62). The
authors hypothesized that the extra HEXIM1 exerted its
eﬀect through inhibition of P-TEFb in a 7SK-dependent
manner; however we (21) and others (18,22,23) have
shown that HEXIM1 is already in excess (2–5-fold) in
most cell lines examined. Knockdown of HEXIM1 had
the opposite eﬀect on HIV LTR expression. Reduction of
HEXIM1 increased the basal, Tat-independent expression
from a transfected HIV LTR and this eﬀect was greater
than with constructs that did not contain early transcribed
HIV sequences (17). Although the authors explained the
increase in expression as a result of the increase in free
P-TEFb, we (21) and others (22) have shown that
knockdown of HEXIM1, even to levels lower than
achieved in the study being discussed, does not lead to
an increase in free P-TEFb. Instead, as HEXIM1 levels
fall, the free HEXIM1 in the cell enters the large form, and
when there is not enough HEXIM1 then HEXIM2 takes
over (21,22). Unknown cellular mechanisms must tightly
regulate amount of P-TEFb activity keeping it at a
constant level. Therefore, the best explanation for the
results from all these studies, given the new understanding
that HEXIM1 binds to TAR, is that there is a direct eﬀect
mediated by HEXIM1 binding to the nascent HIV
transcript.
Hernandez and Pessler (63) discovered this negative
eﬀect of the HIV LTR many years ago. They found that
the ﬁrst 60bp of the transcribed region of the HIV LTR
was an inducer of short transcripts (IST). Unfortunately,
at the time of those ﬁndings, P-TEFb had not been
discovered and mechanisms of RNA polymerase II
elongation control were not understood. It now seems
likely that the IST was a P-TEFb repressor and we now
hypothesize that the mechanism was through HEXIM1
binding to the 50 UTR. There is nothing special about the
HIV promoter in this regard as other promoters driving
the early transcribed region of HIV give rise to short
transcripts and are Tat responsive if TAR is intact (63).
The proposed direct eﬀect of HEXIM1 as a repressor of
P-TEFb through interaction with the HIV 50 UTR may
prove to be exploitable as a target for antiviral treatments.
Latent infections by HIV are the primary reason
that antiviral treatments do not eradicate the virus.
If HEXIM1 can be displaced from the HIV 50 UTR, the
virus might not be able to maintain its latency and would,
therefore, be unable to hide from antiviral treatments.
It may be possible that HEXIM1 release from the HIV 50
UTR and from 7SK may be controlled in the same way.
If so, then treatment of cells with agents that cause
HEXIM1 release would not only relieve HEXIM1-
mediated repression of the HIV LTR, but would also
lead to increased levels of P-TEFb that would also
stimulate HIV transcription even before Tat is produced.
In support of our ﬁnding here, while our manuscript
was in revision another group reported studies that
demonstrated the ability of Tat to cause the release of
P-TEFb from the P-TEFb–HEXIM1–7SK complex (64).
Binding studies were used to demonstrate that an
interaction between amino acids 255–359 of HEXIM1
and a GST fusion containing cyclin T1 (1–292) was
disrupted by Tat and similar results were obtained in vivo
using tagged proteins (64).
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